Skip to main content
Explore URMC

menu

Lymphoma: A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

Research Question:
Is KTE-C19 safe and effective in treating your lymphoma when administered after a 3 day course of chemotherapy?

Basic Study Information

Purpose:
The sponsor is testing an experimental treatment named KTE-C19, which uses the patient’s own genetically altered blood cells to treat cancer. KTE-C19 is made from blood cells that are removed from the patient. A virus (retrovirus) is used to introduce a gene that creates a protein (called a chimeric antigen receptor or CAR) on the surface of T cells, a type of blood cell that fights infection and eliminates cancer cells. The hope is that the CAR on the T cells will bind to and kill cells that express CD19, a molecule that is found on B-cell lymphomas.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02601313?term=Kite+102&rank=1
Study Reference #: ILYM-15080

Lead Researcher (Principal Investigator)

Lead Researcher: Patrick Reagan

Study Contact Information

Study Coordinator: Erin Enfield
Phone: (585) 276-4404
Email: Erin_Enfield@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Lymphoma, Mantle-Cell

More information about Mantle cell lymphoma

Return to Search